معرفی
Professor Andrew Biankin serves as the Regius Chair of Surgery at the University of Glasgow and holds leadership roles including Executive Director of ICGC-ARGO (International Cancer Genome Consortium Accelerating Research in Genomic Oncology) and Specialist Consultant in Precision Oncology. With over 160 publications in major journals, he is a Cancer Research UK Clinician Scientist, Wellcome Trust Senior Investigator, and Fellow of both the Royal Society of Edinburgh and Academy of Medical Sciences.
His research focuses on improving pancreatic cancer outcomes through molecular phenotyping, biomarker implementation, and early detection strategies. As a surgeon-scientist, he leads efforts to characterize genomic, transcriptomic, and epigenomic aberrations in pancreatic cancer, translating these findings into personalized cancer care models where molecular characteristics guide treatment decisions. His work bridges laboratory discoveries with clinical implementation across international health systems.
Analysis of his recent publications reveals strong emphasis on molecular subtyping, DNA damage response mechanisms, and overcoming therapeutic resistance in pancreatic cancer. His team actively develops precision oncology platforms integrating genomic profiling with clinical decision-making, while addressing implementation challenges in real-world healthcare settings. Key themes include biomarker validation, therapeutic targeting of KRAS pathways, and improving access to genomic testing.
- Fellow of the Royal Society of Edinburgh
- Fellow of the Academy of Medical Sciences
- Cancer Research UK Clinician Scientist
- Wellcome Trust Senior Investigator
- Officer of the Order of Australia (A.O.)
Professor Biankin leads the PRECISION-Panc therapeutic development platform and coordinates international consortia including the Australian Pancreatic Cancer Genome Initiative. His research program receives substantial funding from Cancer Research UK, Wellcome Trust, and international agencies supporting genomic oncology. He actively mentors junior researchers and clinicians through formal academic appointments and collaborative networks spanning multiple continents.
His laboratory work centers on the Wolfson Wohl Cancer Research Centre at the University of Glasgow, where his team integrates genomic analysis with functional validation using patient-derived models. The research environment emphasizes cross-disciplinary collaboration between surgeons, oncologists, pathologists, computational biologists, and basic scientists to accelerate translation from bench to bedside.
